Anika Therapeutics (NASDAQ: ANIK) reported Q1 EPS of $0.09, $0.27 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $40.5 million versus the consensus estimate of $41.55 million.

GUIDANCE:

Anika Therapeutics sees FY2024 revenue of $168-173 million, versus the consensus of $170.3 million.

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.